文献速递临床试验与 GCP

静脉注射羧基麦芽糖铁对胃切除术后急性等容量性贫血患者血红蛋白反应的影响:FAIRY随机临床试验

Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

FAIRY试验为患者盲法、随机、3期、安慰剂对照、12周研究,于2013年2月4日至2015年12月15日在韩国7个中心开展。胃切除术后5至7天血清血红蛋白7 g/dL至不足10 g/dL的患者随机接受羧基麦芽糖铁(228例)或生理盐水(226例)。第12周时羧基麦芽糖铁组血红蛋白应答者显著多于安慰剂组(92.2%[200例] vs 54.0%[115例];绝对差异38.2%[95%CI 33.6%-42.8%];P=.001)。

要点

  • 第12周血红蛋白应答者羧基麦芽糖铁组92.2%(200例)vs 安慰剂组54.0%(115例),绝对差异38.2%(95%CI 33.6%-42.8%),P=.001。
  • 第12周血清铁蛋白羧基麦芽糖铁组233.3 ng/mL vs 安慰剂组53.4 ng/mL,绝对差异179.9 ng/mL(95%CI 150.2-209.5),P=.001。
  • 羧基麦芽糖铁组需替代贫血治疗者1.4% vs 安慰剂组6.9%,绝对差异5.5%(95%CI 3.3%-7.6%),P=.006;两组均未报告严重不良事件。

核心结论

  • 在根治性胃切除术后等容量性贫血的成人中,与安慰剂相比,使用羧基麦芽糖糖铁更可能在第12周改善血红蛋白反应。

研究设计与样本

  • FAIRY试验为患者盲法、随机、3期、安慰剂对照、12周研究,于2013年2月4日至2015年12月15日在韩国7个中心开展。
  • 纳入根治性胃切除术后5至7天血清血红蛋白7 g/dL至不足10 g/dL的患者,共随机454例(平均年龄61.1岁;女性54.8%;平均基线血红蛋白9.1 g/dL),96.3%完成试验。
  • 患者随机接受按体重1次或2次注射500 mg或1000 mg羧基麦芽糖铁(羧基麦芽糖铁组228例)或生理盐水(安慰剂组226例)。

主要发现

  • 第12周血红蛋白应答者羧基麦芽糖铁组92.2%(200例)vs 安慰剂组54.0%(115例),绝对差异38.2%(95%CI 33.6%-42.8%),P=.001。
  • 第12周血清铁蛋白羧基麦芽糖铁组233.3 ng/mL vs 安慰剂组53.4 ng/mL,绝对差异179.9 ng/mL(95%CI 150.2-209.5),P=.001。
  • 第12周转铁蛋白饱和度羧基麦芽糖铁组35.0% vs 安慰剂组19.3%,绝对差异15.7%(95%CI 13.1%-18.3%),P=.001。
  • 生活质量方面无显著差异。
  • 需替代贫血管理(口服铁剂、输血或两者)者羧基麦芽糖铁组1.4% vs 安慰剂组6.9%,绝对差异5.5%(95%CI 3.3%-7.6%),P=.006。

关键数值与推荐

  • 主要终点为第12周血红蛋白应答者数量,应答定义为血红蛋白较基线增加2 g/dL或以上、血红蛋白水平11 g/dL或以上或两者兼有。
  • 次要终点包括血红蛋白、铁蛋白和转铁蛋白饱和度随时间的变化、需要替代贫血管理的患者百分比以及第3周和第12周的生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acute isovolemic anemia occurs when blood loss is replaced with fluid. It is often observed after surgery and negatively influences short-term and long-term outcomes. OBJECTIVE: To evaluate the efficacy and safety of ferric carboxymaltose to treat acute isovolemic anemia following gastrectomy. DESIGN, SETTING, AND PARTICIPANTS: The FAIRY trial was a patient-blinded, randomized, phase 3, placebo-controlled, 12-week study conducted between February 4, 2013, and December 15, 2015, in 7 centers across the Republic of Korea. Patients with a serum hemoglobin level of 7 g/dL to less than 10 g/dL at 5 to 7 days following radical gastrectomy were included. INTERVENTIONS: Patients were randomized to receive a 1-time or 2-time injection of 500 mg or 1000 mg of ferric carboxymaltose according to body weight (ferric carboxymaltose group, 228 patients) or normal saline (placebo group, 226 patients). MAIN OUTCOMES AND MEASURES: The primary end point was the number of hemoglobin responders, defined as a hemoglobin increase of 2 g/dL or more from baseline, a hemoglobin level of 11 g/dL or more, or both at week 12. Secondary end points included changes in hemoglobin, ferritin, and transferrin saturation levels over time, percentage of patients requiring alternative anemia management (oral iron, transfusion, or both), and quality of life at weeks 3 and 12. RESULTS: Among 454 patients who were randomized (mean age, 61.1 years; women, 54.8%; mean baseline hemoglobin level, 9.1 g/dL), 96.3% completed the trial. At week 12, the number of hemoglobin responders was significantly greater for ferric carboxymaltose vs placebo (92.2% [200 patients] for the ferric carboxymaltose group vs 54.0% [115 patients] for the placebo group; absolute difference, 38.2% [95% CI, 33.6%-42.8%]; P = .001). Compared with the placebo group, patients in the ferric carboxymaltose group experienced significantly greater improvements in serum ferritin level (week 12: 233.3 ng/mL for the ferric carboxymaltose group vs 53.4 ng/mL for the placebo group; absolute difference, 179.9 ng/mL [95% CI, 150.2-209.5]; P = .001) and transferrin saturation level (week 12: 35.0% for the ferric carboxymaltose group vs 19.3% for the placebo group; absolute difference, 15.7% [95% CI, 13.1%-18.3%]; P = .001); but there were no significant differences in quality of life. Patients in the ferric carboxymaltose group required less alternative anemia management than patients in the placebo group (1.4% for the ferric carboxymaltose group vs 6.9% for the placebo group; absolute difference, 5.5% [95% CI, 3.3%-7.6%]; P = .006). The total rate of adverse events was higher in the ferric carboxymaltose group (15 patients [6.8%], including injection site reactions [5 patients] and urticaria [5 patients]) than the placebo group (1 patient [0.4%]), but no severe adverse events were reported in either group. CONCLUSION AND RELEVANCE: Among adults with isovolemic anemia following radical gastrectomy, the use of ferric carboxymaltose compared with placebo was more likely to result in improved hemoglobin response at 12 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01725789.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kim YW, Bae JM, Park YK, et al. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial. JAMA. 2017. PMID: 28535237. doi:10.1001/jama.2017.5703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。